新冠病毒疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按感染類型、疫苗類型、產品類型、給藥途徑、患者類型、最終用戶、地區和競爭格局分類，2021-2031年

全球新冠疫苗市場預計將從 2025 年的 512.3 億美元成長到 2031 年的 629.7 億美元，複合年成長率為 3.5%。

這些生物製藥利用mRNA、病毒載體、去活化病毒和蛋白質技術等平台，誘導針對SARS-CoV-2病毒的免疫反應，從而預防或減輕COVID-19相關的嚴重程度、住院率和死亡率。市場成長趨勢的主要促進因素包括：病毒變異株的不斷出現需要更新的製劑、政府對研發和分發的大力支持，以及對生產和研發的大量投資。此外，為維持群體免疫而不斷成長的加強疫苗接種需求也是推動市場持續擴張的重要因素。

世界衛生組織（世衛組織）的《全球疫苗市場報告》凸顯了該產業的巨大規模。報告指出，2022年全球共分發了127億劑疫苗，其中77億劑為新冠疫苗。儘管數量如此龐大，但全球疫苗市場進一步成長的主要障礙仍然是疫苗分配不均。這種不平衡的分配造成了疫苗取得的巨大差距，並對低收入國家的人民造成了不成比例的影響。

市場促進因素

全球新冠疫苗市場的主要驅動力是不斷湧現的新病毒變種。這要求疫苗必須持續調整，以維持對這些變異株的有效性。這種瞬息萬變的情況促使製藥公司加快研發和部署改良疫苗，以確保對預防性免疫的穩定需求。對更新疫苗的持續需求為生產者提供了可靠的收入來源，也凸顯了市場如何適應這項生物威脅。例如，在2026年2月發布的題為「輝瑞公司公佈強勁的2025年全年業績並重申2026年展望」的新聞稿中，輝瑞公司預測，2026年新冠相關產品的收入將達到約50億美元，強調了對抗不斷演變的病毒所需的疫苗的持續需求。

同時，加大研發投入在市場成長中發揮著至關重要的作用，它加速了技術進步，並能夠對新出現的公共衛生危機做出快速反應。製藥公司正投入大量資金用於研發，以提高疫苗穩定性、改善給藥系統，並探索下一代預防措施，例如聯合疫苗。這些努力對於延長免疫持續時間和建立應對未來疫情的防禦體系至關重要。為了體現這些推動研發的努力，輝瑞在2024年12月發布的新聞稿《輝瑞發布2025年全年展望，重申2024年全年展望》中預測，2025年全年調整後的研發支出將在107億美元至117億美元之間。整體而言，疫苗產業整體依然非常活躍。根據全球健康新聞社2026年4月報道，預計2025年至2026年全球疫苗年產量將達到約145億劑。

市場挑戰

全球新冠疫苗分配不均是全球市場持續擴張的一大障礙。這個問題源自於產能和整體供應量的巨大差異，尤其對低收入國家造成嚴重影響。這些地區嚴重依賴外部疫苗採購，經常面臨供應鏈脆弱性和關鍵疫苗供應不穩定的問題。

世界衛生組織（世衛組織）的《全球疫苗市場報告》印證了這個問題，報告顯示，到2024年，世衛組織非洲區域和東地中海區域的國家將幾乎全部（超過95%）的疫苗供應依賴進口，而這些疫苗均來自境外生產商。這種對外部生產的過度依賴阻礙了穩健的區域疫苗市場的形成和自給自足生產網路的建立。因此，這種依賴性常常導致疫苗供應延遲和物流複雜化，直接阻礙了這些人口稠密地區有效的免疫接種工作和長期市場滲透。最終，無法充分利用需求並在所有區域部門建立可靠的分銷管道，阻礙了全球市場更廣泛地擴張。

市場趨勢

市場關鍵趨勢之一是聚焦於泛冠狀病毒疫苗的研究。該疫苗旨在提供對現有和新出現的SARS-CoV-2變種以及其他冠狀病毒的全面且長期的保護。透過靶向能夠觸發廣泛免疫反應的保守病毒元件，這項科學研究旨在打破不斷更新疫苗以應對特定變種的惡性循環，並提供更穩定、更持久的解決方案。研發通用疫苗是一項策略性舉措，旨在減輕新變種帶來的社會影響，並簡化疫苗供應的物流。為了強調實現持久免疫的努力，哥倫比亞廣播公司新聞（CBS News）在2025年5月報道稱，美國國立衛生研究院（NIH）此前已向七所大學的研究人員津貼6240萬美元，用於開展泛冠狀病毒疫苗的研究。

全球新冠疫苗市場也正受到非注射製劑研發的影響，這些製劑能夠提高病患依從性和整體可近性。滴鼻劑和口服疫苗等替代給藥方式簡化了接種流程，並有助於更廣泛地分發，尤其對於那些害怕注射的人。此外，鼻內給藥的黏膜疫苗可以直接在病毒入侵的最初部位誘發局部免疫，從而為預防感染和傳播增加一層保護。一篇發表於2026年4月的專業新聞報導《加速下一代新冠疫苗的研發》強調了這種向更便捷、更有效的途徑轉變的趨勢，該文章重點介紹了六份關於粘膜疫苗的臨床前報告，展現了該領域目前活躍的研究和開發現狀。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球新冠病毒疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依感染疾病類型（SARS-CoV-2、SARS-CoV、MERS-CoV）
  • 疫苗類型（病毒疫苗、病毒載體疫苗、核酸疫苗、蛋白質疫苗、其他）
  • 依產品類型（單價疫苗與多價疫苗）
  • 給藥途徑（肌肉注射、口服、鼻腔給藥）
  • 依患者類型（成人與兒童）
  • 依最終使用者（醫院、診所、研究機構等）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美新冠疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲新冠疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區新冠病毒疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲新冠疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲新冠疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球新冠病毒疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc.
• BioNTech SE
• Moderna, Inc.
• AstraZeneca PLC
• Johnson & Johnson Services Inc.
• Novavax, Inc.
• Sinovac Biotech Ltd.
• Sinopharm Group Co., Ltd.
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Coronavirus Vaccine Market is anticipated to expand from USD 51.23 billion in 2025 to USD 62.97 billion by 2031, reflecting a compound annual growth rate (CAGR) of 3.5%. These biological products stimulate an immune response against the SARS-CoV-2 virus to prevent or reduce the severity, hospitalization rates, and mortality associated with COVID-19, utilizing platforms such as mRNA, viral vectors, inactivated viruses, and protein-based techniques. The market's upward trajectory is largely fueled by the continuous emergence of viral variants that require updated formulations, along with strong government backing for development and distribution, and heavy investments in manufacturing and research. Additionally, the growing need for booster shots to sustain population immunity significantly contributes to this ongoing market expansion.

Highlighting the immense scale of this sector, the World Health Organization's Global Vaccine Market Report noted that COVID-19 vaccines accounted for 7.7 billion of the 12.7 billion total vaccine doses distributed worldwide in 2022. Despite this massive volume, a major obstacle to broader global market growth remains the unequal distribution of these vaccines. This uneven allocation creates significant access gaps, disproportionately affecting the populations of lower-income nations.

Market Driver

A major force propelling the Global Coronavirus Vaccine Market is the continuous emergence of new viral variants, which requires constant adjustments to vaccines to preserve their effectiveness against shifting strains. This ever-changing landscape drives pharmaceutical firms to speed up the creation and rollout of revised vaccine versions, securing a steady demand for protective immunity. The persistent requirement for these updated vaccines provides reliable revenue generation for producers, highlighting how the market adapts to biological threats. As an example, Pfizer Inc. noted in its February 2026 press release, 'Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance,' that it projects roughly $5 billion in revenue from its COVID-19 offerings in 2026, underscoring the enduring need for vaccines to combat ongoing viral evolution.

At the same time, heightened research and development efforts play a vital role in market growth by driving technological improvements and allowing for swifter reactions to emerging public health crises. Pharmaceutical companies are pouring substantial funds into R&D to boost vaccine stability, refine delivery systems, and investigate next-generation preventive options like combination vaccines. These efforts are essential for prolonging immunity and readying defenses for future outbreaks. Highlighting this dedication to progress, Pfizer Inc.'s December 2024 press release, 'Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance,' forecasted full-year 2025 Adjusted Research and Development spending between $10.7 billion and $11.7 billion. Overall, the wider vaccine industry remains highly active; according to Global Health Press in April 2026, worldwide vaccine manufacturing is estimated to reach approximately 14.5 billion doses annually for the 2025 to 2026 period.

Market Challenge

The uneven global distribution of coronavirus vaccines stands as a major hurdle to the continuous expansion of the global market. This issue stems from stark differences in production capacity and overall accessibility, which take a particularly heavy toll on lower-income countries. Because these regions depend so heavily on purchasing vaccines from outside sources, they frequently face supply chain vulnerabilities and inconsistent availability of critical doses.

Illustrating this problem, the World Health Organization's Global Vaccine Market Report revealed that in 2024, nations within the WHO African and Eastern Mediterranean regions imported nearly all, over 95%, of their vaccine supply from producers outside their respective borders. This intense reliance on external manufacturing stifles the creation of strong regional vaccine markets and independent production networks. Consequently, this dependency often leads to delayed vaccine availability and complicated logistics, directly hindering dependable immunization initiatives and long-term market penetration in these highly populated areas. Ultimately, the broader global market's expansion is held back by the inability to fully capitalize on demand and build reliable distribution channels across all geographic sectors.

Market Trends

A major trend in the market is the focus on pan-coronavirus vaccine research, which seeks to provide comprehensive and long-lasting defense against existing and upcoming SARS-CoV-2 variants, as well as potentially other coronaviruses. By targeting conserved viral elements that trigger a broad immune reaction, this scientific effort aims to break the continuous cycle of updating vaccines for specific variants, delivering a more stable and permanent solution. Moving toward universal vaccines is a strategic effort to lessen the societal damage caused by new strains and to simplify the logistics of vaccine distribution. Highlighting the dedication to achieving enduring immunity, CBS News reported in May 2025 that the National Institutes of Health had previously granted $62.4 million to researchers at seven different universities working on pan-coronavirus vaccines.

The Global coronavirus vaccine market is also being shaped by the growing development of non-injectable formulations, which improve both patient compliance and overall accessibility. Alternative administration techniques, such as nasal sprays and oral vaccines, make the process easier and facilitate wider distribution, especially among populations with a fear of needles. Furthermore, mucosal vaccines delivered intranasally can induce localized immunity directly at the primary site of viral entry, adding an extra layer of protection against both infection and transmission. Emphasizing this shift toward more user-friendly and powerful approaches, an April 2026 specialized news update titled 'Accelerating Development for Some NextGen Covid Vaxes' highlighted six preclinical reports focused on mucosal vaccines, reflecting intense ongoing research and development in this space.

Key Market Players

• Pfizer Inc.
• BioNTech SE
• Moderna, Inc.
• AstraZeneca PLC
• Johnson & Johnson Services Inc.
• Novavax, Inc.
• Sinovac Biotech Ltd.
• Sinopharm Group Co., Ltd.
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd.

Report Scope

In this report, the Global Coronavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Coronavirus Vaccine Market, By Infection Type

• SARS-CoV-2
• SARS-CoV
• MERS-CoV

Coronavirus Vaccine Market, By Vaccine Type

• Virus Vaccine
• Viral Vector Vaccine
• Nucleic Acid Vaccine
• Protein Based Vaccine
• Others

Coronavirus Vaccine Market, By Product Type

• Monovalent Vaccine
• Multivariant Vaccine

Coronavirus Vaccine Market, By Route of Administration

• Intramuscular
• Oral
• Intranasal

Coronavirus Vaccine Market, By Patient Type

• Adults
• Pediatric

Coronavirus Vaccine Market, By End User

• Hospitals
• Clinics
• Research Institutes
• Others

Coronavirus Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Coronavirus Vaccine Market.

Available Customizations:

Global Coronavirus Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Coronavirus Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV)
  • 5.2.2. By Vaccine Type (Virus Vaccine, Viral Vector Vaccine, Nucleic Acid Vaccine, Protein Based Vaccine, Others)
  • 5.2.3. By Product Type (Monovalent Vaccine v/s Multivariant Vaccine)
  • 5.2.4. By Route of Administration (Intramuscular, Oral, Intranasal)
  • 5.2.5. By Patient Type (Adults v/s Pediatric)
  • 5.2.6. By End User (Hospitals, Clinics, Research Institutes, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2025)
• 5.3. Market Map

6. North America Coronavirus Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Infection Type
  • 6.2.2. By Vaccine Type
  • 6.2.3. By Product Type
  • 6.2.4. By Route of Administration
  • 6.2.5. By Patient Type
  • 6.2.6. By End User
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Coronavirus Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Infection Type
      • 6.3.1.2.2. By Vaccine Type
      • 6.3.1.2.3. By Product Type
      • 6.3.1.2.4. By Route of Administration
      • 6.3.1.2.5. By Patient Type
      • 6.3.1.2.6. By End User
  • 6.3.2. Canada Coronavirus Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Infection Type
      • 6.3.2.2.2. By Vaccine Type
      • 6.3.2.2.3. By Product Type
      • 6.3.2.2.4. By Route of Administration
      • 6.3.2.2.5. By Patient Type
      • 6.3.2.2.6. By End User
  • 6.3.3. Mexico Coronavirus Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Infection Type
      • 6.3.3.2.2. By Vaccine Type
      • 6.3.3.2.3. By Product Type
      • 6.3.3.2.4. By Route of Administration
      • 6.3.3.2.5. By Patient Type
      • 6.3.3.2.6. By End User

7. Europe Coronavirus Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Infection Type
  • 7.2.2. By Vaccine Type
  • 7.2.3. By Product Type
  • 7.2.4. By Route of Administration
  • 7.2.5. By Patient Type
  • 7.2.6. By End User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Coronavirus Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Infection Type
      • 7.3.1.2.2. By Vaccine Type
      • 7.3.1.2.3. By Product Type
      • 7.3.1.2.4. By Route of Administration
      • 7.3.1.2.5. By Patient Type
      • 7.3.1.2.6. By End User
  • 7.3.2. France Coronavirus Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Infection Type
      • 7.3.2.2.2. By Vaccine Type
      • 7.3.2.2.3. By Product Type
      • 7.3.2.2.4. By Route of Administration
      • 7.3.2.2.5. By Patient Type
      • 7.3.2.2.6. By End User
  • 7.3.3. United Kingdom Coronavirus Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Infection Type
      • 7.3.3.2.2. By Vaccine Type
      • 7.3.3.2.3. By Product Type
      • 7.3.3.2.4. By Route of Administration
      • 7.3.3.2.5. By Patient Type
      • 7.3.3.2.6. By End User
  • 7.3.4. Italy Coronavirus Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Infection Type
      • 7.3.4.2.2. By Vaccine Type
      • 7.3.4.2.3. By Product Type
      • 7.3.4.2.4. By Route of Administration
      • 7.3.4.2.5. By Patient Type
      • 7.3.4.2.6. By End User
  • 7.3.5. Spain Coronavirus Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Infection Type
      • 7.3.5.2.2. By Vaccine Type
      • 7.3.5.2.3. By Product Type
      • 7.3.5.2.4. By Route of Administration
      • 7.3.5.2.5. By Patient Type
      • 7.3.5.2.6. By End User

8. Asia Pacific Coronavirus Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Infection Type
  • 8.2.2. By Vaccine Type
  • 8.2.3. By Product Type
  • 8.2.4. By Route of Administration
  • 8.2.5. By Patient Type
  • 8.2.6. By End User
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Coronavirus Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Infection Type
      • 8.3.1.2.2. By Vaccine Type
      • 8.3.1.2.3. By Product Type
      • 8.3.1.2.4. By Route of Administration
      • 8.3.1.2.5. By Patient Type
      • 8.3.1.2.6. By End User
  • 8.3.2. India Coronavirus Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Infection Type
      • 8.3.2.2.2. By Vaccine Type
      • 8.3.2.2.3. By Product Type
      • 8.3.2.2.4. By Route of Administration
      • 8.3.2.2.5. By Patient Type
      • 8.3.2.2.6. By End User
  • 8.3.3. Japan Coronavirus Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Infection Type
      • 8.3.3.2.2. By Vaccine Type
      • 8.3.3.2.3. By Product Type
      • 8.3.3.2.4. By Route of Administration
      • 8.3.3.2.5. By Patient Type
      • 8.3.3.2.6. By End User
  • 8.3.4. South Korea Coronavirus Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Infection Type
      • 8.3.4.2.2. By Vaccine Type
      • 8.3.4.2.3. By Product Type
      • 8.3.4.2.4. By Route of Administration
      • 8.3.4.2.5. By Patient Type
      • 8.3.4.2.6. By End User
  • 8.3.5. Australia Coronavirus Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Infection Type
      • 8.3.5.2.2. By Vaccine Type
      • 8.3.5.2.3. By Product Type
      • 8.3.5.2.4. By Route of Administration
      • 8.3.5.2.5. By Patient Type
      • 8.3.5.2.6. By End User

9. Middle East & Africa Coronavirus Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Infection Type
  • 9.2.2. By Vaccine Type
  • 9.2.3. By Product Type
  • 9.2.4. By Route of Administration
  • 9.2.5. By Patient Type
  • 9.2.6. By End User
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Coronavirus Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Infection Type
      • 9.3.1.2.2. By Vaccine Type
      • 9.3.1.2.3. By Product Type
      • 9.3.1.2.4. By Route of Administration
      • 9.3.1.2.5. By Patient Type
      • 9.3.1.2.6. By End User
  • 9.3.2. UAE Coronavirus Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Infection Type
      • 9.3.2.2.2. By Vaccine Type
      • 9.3.2.2.3. By Product Type
      • 9.3.2.2.4. By Route of Administration
      • 9.3.2.2.5. By Patient Type
      • 9.3.2.2.6. By End User
  • 9.3.3. South Africa Coronavirus Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Infection Type
      • 9.3.3.2.2. By Vaccine Type
      • 9.3.3.2.3. By Product Type
      • 9.3.3.2.4. By Route of Administration
      • 9.3.3.2.5. By Patient Type
      • 9.3.3.2.6. By End User

10. South America Coronavirus Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Infection Type
  • 10.2.2. By Vaccine Type
  • 10.2.3. By Product Type
  • 10.2.4. By Route of Administration
  • 10.2.5. By Patient Type
  • 10.2.6. By End User
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Coronavirus Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Infection Type
      • 10.3.1.2.2. By Vaccine Type
      • 10.3.1.2.3. By Product Type
      • 10.3.1.2.4. By Route of Administration
      • 10.3.1.2.5. By Patient Type
      • 10.3.1.2.6. By End User
  • 10.3.2. Colombia Coronavirus Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Infection Type
      • 10.3.2.2.2. By Vaccine Type
      • 10.3.2.2.3. By Product Type
      • 10.3.2.2.4. By Route of Administration
      • 10.3.2.2.5. By Patient Type
      • 10.3.2.2.6. By End User
  • 10.3.3. Argentina Coronavirus Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Infection Type
      • 10.3.3.2.2. By Vaccine Type
      • 10.3.3.2.3. By Product Type
      • 10.3.3.2.4. By Route of Administration
      • 10.3.3.2.5. By Patient Type
      • 10.3.3.2.6. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Coronavirus Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BioNTech SE
• 15.3. Moderna, Inc.
• 15.4. AstraZeneca PLC
• 15.5. Johnson & Johnson Services Inc.
• 15.6. Novavax, Inc.
• 15.7. Sinovac Biotech Ltd.
• 15.8. Sinopharm Group Co., Ltd.
• 15.9. Bharat Biotech International Limited
• 15.10. Serum Institute of India Pvt. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer